News

Mosanna Therapeutics Reports Positive Results from the Phase 1 MOSAIC Study of MOS118 for Obstructive Sleep Apnea

•September 29, 2026

Mosanna Therapeutics Launches with $80 Million to Advance Novel Nighttime Nasal Spray for Obstructive Sleep Apnea

•June 9, 2025